Glaukos Corp (Glaukos) is an ophthalmic medical device company that researches and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as micro stent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- to moderate-open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Canada, the UK, Australia, Brazil and Japan, among others. Glaukos is headquartered in San Clemente, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Glaukos Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Glaukos Corp Company Overview
- Glaukos Corp Company Snapshot
- Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview
- Glaukos Corp - Pipeline Analysis Overview
- Glaukos Corp - Key Facts
- Glaukos Corp - Major Products and Services
- Glaukos Corp Pipeline Products by Development Stage
- Glaukos Corp Ongoing Clinical Trials by Trial Status
- Glaukos Corp Pipeline Products Overview
- Brillouin Scanning Microscope
- Brillouin Scanning Microscope Product Overview
- iDose Rock
- iDose Rock Product Overview
- iDose TR Travoprost Intraocular Implant
- iDose TR Travoprost Intraocular Implant Product Overview
- iDose TR Travoprost Intraocular Implant Clinical Trial
- iDose TREX
- iDose TREX Product Overview
- IOP Sensor System
- IOP Sensor System Product Overview
- iStent SA Trabecular Micro-Bypass System
- iStent SA Trabecular Micro-Bypass System Product Overview
- Mosaic System - Presbyopia
- Mosaic System - Presbyopia Product Overview
- Oxygen Enrichment Device
- Oxygen Enrichment Device Product Overview
- Glaukos Corp - Key Competitors
- Glaukos Corp - Key Employees
- Glaukos Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Glaukos Corp, Recent Developments
- Feb 01, 2023: Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
- Sep 28, 2022: Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
- Mar 14, 2022: Glaukos announces commencement of phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapy
- Dec 20, 2021: Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
- Nov 04, 2021: Glaukos Announces Third Quarter 2021 Financial Results
- Aug 26, 2021: Glaukos Announces Participation in the Wells Fargo Healthcare Conference
- Aug 05, 2021: Glaukos Announces Second Quarter 2021 Financial Results
- Jul 15, 2021: Glaukos to Release Second Quarter 2021 Financial Results after Market Close on August 5
- Jul 14, 2021: Glaukos comments on the Centers for Medicare and Medicaid Services 2022 proposed physician fee schedule
- May 18, 2021: Glaukos expands its PRESERFLO MicroShunt relationship with Santen via new license agreement
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview
- Glaukos Corp Pipeline Products by Equipment Type
- Glaukos Corp Pipeline Products by Indication
- Glaukos Corp Ongoing Clinical Trials by Trial Status
- Glaukos Corp, Key Facts
- Glaukos Corp, Major Products and Services
- Glaukos Corp Number of Pipeline Products by Development Stage
- Glaukos Corp Pipeline Products Summary by Development Stage
- Glaukos Corp Ongoing Clinical Trials by Trial Status
- Glaukos Corp Ongoing Clinical Trials Summary
- Brillouin Scanning Microscope - Product Status
- Brillouin Scanning Microscope - Product Description
- iDose Rock - Product Status
- iDose Rock - Product Description
- iDose TR Travoprost Intraocular Implant - Product Status
- iDose TR Travoprost Intraocular Implant - Product Description
- iDose TR Travoprost Intraocular Implant - Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure
- iDose TREX - Product Status
- iDose TREX - Product Description
- IOP Sensor System - Product Status
- IOP Sensor System - Product Description
- iStent SA Trabecular Micro-Bypass System - Product Status
- iStent SA Trabecular Micro-Bypass System - Product Description
- Mosaic System - Presbyopia - Product Status
- Mosaic System - Presbyopia - Product Description
- Oxygen Enrichment Device - Product Status
- Oxygen Enrichment Device - Product Description
- Glaukos Corp, Key Employees
- Glaukos Corp, Subsidiaries
- Glossary
- Glaukos Corp Pipeline Products by Equipment Type
- Glaukos Corp Pipeline Products by Development Stage
- Glaukos Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- STAAR Surgical Company
- Cyberonics Inc
- IRIDEX Corporation (US)
